Archives
-
mRNA-LNP CMC: From Formulation to Translation
2026-10-08
This 2026 review frames mRNA–lipid nanoparticle translation as an integrated chemistry, manufacturing, and controls problem rather than a formulation-only challenge. Its central contribution is a CMC-oriented map linking lipid chemistry, process behavior, critical quality attributes, analytical characterization, stability, and scale-up comparability to clinical and regulatory readiness.
-
SMPD4, Ceramide, and Primary Cilia in Brain Development
2026-10-07
A 2024 Development study links SMPD4-dependent sphingolipid metabolism to ceramide availability, primary cilium integrity, neural progenitor survival, and cerebellar development. By combining a mouse model with human induced pluripotent stem cell evidence, the study proposes a mechanistic explanation for brain malformations associated with SMPD4 variants while defining important boundaries for translation.
-
Deracoxib in Canine Cancer and Inflammation Research
2026-10-07
Deracoxib is a selective COX-2 inhibitor with established relevance to veterinary pain and inflammation research, but its anticancer evidence remains primarily preclinical. In a 2012 study of the CMT-U27 canine mammary carcinoma cell line, deracoxib reduced viability and increased apoptosis at higher in-vitro exposures, while combination with piroxicam produced stronger growth inhibition than either drug alone. These findings support mechanistic and hypothesis-generating research, not clinical conclusions about canine cancer treatment.
-
EZ Cap™ Human PTEN mRNA: Evidence and Limits
2026-10-06
This overview places EZ Cap™ Human PTEN mRNA (ψUTP) in the context of preclinical research on PTEN restoration, trastuzumab resistance, and nanoparticle-mediated delivery. It distinguishes supplier-described product features from findings reported in a breast cancer study and outlines the evidence gaps that limit broader interpretation.
-
AO/PI Double Staining Kit: Product Overview
2026-10-06
The AO/PI Double Staining Kit (SKU K2238) is a supplier-described fluorescent cell staining kit using Acridine Orange and Propidium Iodide to classify cells by membrane integrity and fluorescence patterns. No matched research paper was provided, so performance and broader applicability remain unverified.
-
Lysosomal β-Galactosidase Staining in Senescence Research
2026-10-05
Lysosomal β-galactosidase staining can provide a useful morphological readout in cellular senescence and chemoresistance studies, but blue X-gal signal is not sufficient to establish a senescent phenotype. This overview examines the conceptual role of the APExBIO Lysosomal β-Galactosidase Staining Kit alongside findings from a 2026 article-in-press on SLC25A1, cisplatin resistance, and senescence in head and neck squamous cell carcinoma.
-
Schwartz on Measuring Cancer Drug Responses
2026-10-05
Hannah Schwartz’s 2022 dissertation argues that in vitro cancer drug responses should be separated into proliferation arrest and actual cell killing rather than summarized by a single viability value. Its central contribution is a measurement framework that emphasizes response composition and timing, improving interpretation of pharmacological data while clarifying the limits of conventional viability assays.
-
Zoledronic Acid: From Apoptosis to Translation
2026-10-04
Zoledronic Acid is best understood not simply as a cytotoxic reagent, but as a translational probe connecting tumor-cell apoptosis, bone-microenvironment biology, and evidence-led biomarker development. This perspective examines what current findings support, where uncertainty remains, and how the molecule can inform more disciplined cancer and bone research.
-
Radioiodinated Balsalazide for Ulcerative Colitis Imaging
2026-10-02
The reference study developed and evaluated radioiodinated balsalazide as a colon-targeted tracer for ulcerative colitis in mice. Its optimized labeling conditions, 24-hour stability, and strong uptake in ulcerated colon support a practical imaging strategy while also highlighting important limits for translation beyond animal biodistribution studies.
-
A 83-01 (ALK inhibitor) Assay Guide
2026-10-01
This scenario-driven guide explains how A 83-01 (ALK inhibitor), SKU A3133, can improve interpretation of cell viability, proliferation, cytotoxicity, EMT, and stem-cell differentiation experiments. It combines product specifications with quantitative pathway evidence and practical controls for solvent handling, dose selection, and vendor evaluation.
-
Bradykinin B2 Receptors and Ileal Peristalsis
2026-10-01
The reference study provides direct pharmacological evidence that bradykinin inhibits the guinea pig ileal peristaltic reflex through B2 receptors rather than B1 receptors. Its pressure-threshold assay and antagonist comparisons offer a useful framework for separating receptor-specific effects on intestinal motility from broader smooth-muscle responses.
-
AP20187 Chemical Inducer of Dimerization Guide
2026-09-30
AP20187 gives researchers temporal control over engineered signaling proteins, enabling conditional gene expression, reporter activation, and regulated cell therapy workflows. This guide connects practical dimerizer handling with assay design lessons from chronic intermittent hypoxia research while clearly separating validated evidence from proposed applications.
-
In Vitro Drug Response Metrics in Cancer Research
2026-09-30
Hannah Schwartz’s dissertation distinguishes relative viability from fractional viability, showing that growth arrest and cell killing are related but non-equivalent components of an anticancer response. This framework supports better time-resolved interpretation of drug assays and helps researchers avoid treating reduced metabolic or cell-count readouts as direct measures of cytotoxicity.
-
NAD+/NADH Homeostasis in Fungal Hypoxia
2026-09-29
This 2018 award review explains how NAD+/NADH homeostasis links oxygen availability with glycolysis, fermentation, energy conservation, and secondary metabolite production in filamentous fungi. Its central contribution is a mechanistic framework connecting hypoxia-driven redox imbalance with NAD+ degradation, sirtuin A regulation, and biotechnologically important fungal outputs.
-
Bifendate (DDB): Applied Liver Research Workflows
2026-09-29
Bifendate (DDB) is a versatile liver-research perturbagen for connecting hepatoprotection, lipid metabolism, and autophagy studies in the same experimental plan. This workflow emphasizes dose- and time-dependent interpretation, fresh solution handling, paired serum–liver measurements, and controls that prevent high-dose triglyceride responses from being mistaken for assay failure.